Paris, the 13 June 2017 • Enovap, in partnership with Limsi (CNRS multidisciplinary computer science research laboratory), is developing artificial intelligence capable of testing different methods of smoking cessation. A strong commitment to R&D for the startup Enovap, which reflects its desire to participate in the fight against tobacco.
In order to reinforce the effectiveness of its device, Enovap, the first intelligent e-cigarette allowing the management of the nicotine intake (patented technology), has decided to enrich its mobile application. This includes an automatic reduction mode to better support people wishing to quit smoking.
In this context, Enovap has initiated a partnership with the Computer Science Laboratory for Mechanics and Engineering Sciences (LIMSI) to develop artificial intelligence and develop a real platform to support smoking cessation.
The expertise of the CNRS in the fields of machine learning and artificial intelligence allows Enovap to lead the project with all the required knowledge. The development of weaning algorithms and the monitoring platform, features unique to Enovap, reinforce its position as an innovative company in the electronic cigarette sector.
In fact, this R&D program will allow it to soon offer a personalized coach adapting to the user's profile. This coach, by analyzing the consumption profile (quantity of nicotine inhaled, places, times, circumstances, etc.), will suggest different withdrawal methods and assess their effectiveness.
For Alexandre Scheck, CEO of Enovap: “ Ultimately and thanks to Limsi's skills in machine learning, this artificial intelligence will be able to develop, independently, new weaning methods adapted to each one."
Led by Jean-Batiste Corrégé and supervised by Mehdi Ammi, Engineer in electronics, Doctor in robotics, and authorized to direct research in Human-Machine interaction (IT), within Limsi, the project also involves Céline Clavel, Associate Professor specializing in cognitive psychology.
« This multidisciplinary approach is certainly what prompted us to propose this subject with the Limsi within the framework of a specific European call for projects. “FEDER 2017” specifies Marie Harang-Eltz, Chief Scientific Officer at Enovap.
About LIMSI
About Enovap
Founded in 2015, Enovap is a French startup developing a unique and innovative personal vaporizer. Enovap's mission is to help smokers in their quest to quit smoking by providing them with optimal satisfaction thanks to its patented technology. This technology makes it possible to manage and anticipate the dose of nicotine delivered by the device at any given moment, thus meeting the user's needs. Enovap technology was awarded the gold medal at the Lépine Competition (2014) and the Seal Of Excellence from the European Commission within the framework of the H2020 projects.
